The Patent Finder

Chatham Biotec, Limited

Also on record
Records under this name other than patents Chatham Biotec, Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 9 of 9 · Back to Chatham Biotec, Limited

PatentTitleStatus Expires Confidence
US 8,592,588Process to prepare camptothecin derivatives
Lapsed on the fee record
Ended Nov 26, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 26, 2025From the USPTO record
US 8,299,279Semi-synthetic process for the preparation of taxane derivatives
Lapsed on the fee record
Ended Oct 30, 2020 · From the USPTO record
Lapsed on the fee recordEnded Oct 30, 2020From the USPTO record
US 8,293,930One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel
Lapsed on the fee record
Ended Oct 23, 2020 · From the USPTO record
Lapsed on the fee recordEnded Oct 23, 2020From the USPTO record
US 7,906,661Semi-synthetic conversion of paclitaxel to docetaxel
Lapsed on the fee record
Ended Mar 15, 2019 · From the USPTO record
Lapsed on the fee recordEnded Mar 15, 2019From the USPTO record
US 7,893,283Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel
Lapsed on the fee record
Ended Feb 22, 2019 · From the USPTO record
Lapsed on the fee recordEnded Feb 22, 2019From the USPTO record
US 7,838,694Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes
Lapsed on the fee record
Ended Nov 23, 2018 · From the USPTO record
Lapsed on the fee recordEnded Nov 23, 2018From the USPTO record
US 6,222,053Semi-synthesis of a protected baccatin III compound
Term ended
Term ended Oct 17, 2017 · From the USPTO record
Term endedTerm ended Oct 17, 2017From the USPTO record
US 6,576,777Semi-synthesis of a protected baccatin III compound
Term ended
Term ended Oct 17, 2017 · From the USPTO record
Term endedTerm ended Oct 17, 2017From the USPTO record
US 7,585,986Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
Lapsed on the fee record
Ended Sep 8, 2017 · From the USPTO record
Lapsed on the fee recordEnded Sep 8, 2017From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited